| Through new drug launches, panel discussions, and similar forums. | 患者倡議
> 藥物及相關治療 | 監管合作夥伴關係
> 與監管機構合作 | 1,000 | Regional | Sometimes | 115028447628 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | National | Regularly | 114998266569 |
| We assess cost-effectiveness. | 肝臟
> 肝臟疾病：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Sometimes | 114998327089 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | 一般健康
> 醫療服務提供 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 115009387424 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 10,000 | National | Regularly | 114998266569 |
| Attendance at relevant committee meetings and informal consultative sessions. | 先天性
> 先天性：心臟 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 10,000 | National | Rarely | 115003445044 |
| Activities include policy forums, stakeholder consultations, meetings with relevant government ministries, and related engagements. | 罕見
> 罕見疾病：大多數類型 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 1,000 | National | Regularly | 115033450975 |
| Convening public hearings in the National Assembly and submitting formal recommendations to the Ministry of Health and Welfare [in Korea]. | 心理健康
> 精神健康：大多數狀況 | 影響政策及立法
> 影響醫療保健政策及立法 | 5,000 | Regional | Sometimes | 115019561629 |
| Activities included participation in policy forums advocating for the reimbursement of treatments currently excluded from public health insurance coverage, including Durvalumab and the graft-versus-host disease treatment Belumosudil. | 癌症
> 癌症：血液 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 100,000 | Regional | Sometimes | 115008918207 |
| Convening of National Assembly public hearings. | 心理健康
> 精神健康：大多數狀況 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 5,000 | Regional | Sometimes | 115019561629 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | 癌症
> 癌症：血液 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 1,000 | Regional | Sometimes | 115028455157 |
| Activities include participation in forums and debates, submission of petitions to the 인권위 [국가인권위원회 – National Human Rights Commission]. | 患者倡議
> 病人權利 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 5,000 | Regional | Regularly | 115033350867 |
| Participated in a National Assembly policy forum on medicines not covered by public health insurance to convey the patient perspective. | 癌症
> 癌症：乳腺癌 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 5,000 | National | Sometimes | 115058944486 |
| A request for the re-listing of a Parkinson's disease treatment. | 神經退行性
> 柏金遜症 | 影響政策及立法
> 處理醫療護理中的障礙/異常情況 | 5,000 | National | Rarely | 115055431165 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | 癌症
> 癌症：大多數類型 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 10,000 | National | Regularly | 114998266569 |
| Participated in a National Assembly policy debate on non-reimbursable drugs to convey patients' voices, and engaged in a petition drive to advocate for reimbursement coverage. | 癌症
> 癌症：乳腺癌 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 5,000 | National | Sometimes | 115058944486 |
| We assess cost-effectiveness. | 肝臟
> 肝臟疾病：大多數類型 | 定價及可負擔性倡議
> 參與價格審查委員會談判 | 100,000 | National | Sometimes | 114998327089 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | 癌症
> 癌症：血液 | 定價及可負擔性倡議
> 參與價格審查委員會談判 | 1,000 | Regional | Sometimes | 115028455157 |
| Reimbursement rates for basic welfare recipients. | 心理健康
> 精神健康：大多數狀況 | 定價及可負擔性倡議
> 解決低收入及弱勢群體的費用負擔問題 | 5,000 | Regional | Sometimes | 115021952415 |
| Inclusion of medical devices — such as continuous glucose monitors and insulin pumps — on the national health insurance formulary. | 內分泌
> 糖尿病：第1型 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 100,000 | National | No | 114998267322 |
| Activities included participation in policy forums advocating for the reimbursement of treatments currently excluded from public health insurance coverage, including Durvalumab [help the body's immune system recognize and destroy cancer] and the graft-versus-host disease treatment Belumosudil. | 癌症
> 癌症：血液 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 100,000 | Regional | Sometimes | 115008918207 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | 癌症
> 癌症：血液 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 1,000 | Regional | Sometimes | 115028455157 |
| Participated in a National Assembly policy debate on non-reimbursable drugs to convey patients' voices, and engaged in a petition drive to advocate for reimbursement coverage. | 癌症
> 癌症：乳腺癌 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 5,000 | National | Sometimes | 115058944486 |
| A request for the re-listing of a Parkinson's disease treatment. | 神經退行性
> 柏金遜症 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 5,000 | National | Rarely | 115055431165 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | 一般健康
> 醫療服務提供 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | 100,000 | National | Regularly | 115009387424 |
| We submit written recommendations on a regular basis. | 癌症
> 癌症：血液 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | 10,000 | National | Regularly | 115056090120 |
| Participated in a National Assembly policy forum on medicines not covered by public health insurance to convey the patient perspective. | 癌症
> 癌症：乳腺癌 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | 5,000 | National | Sometimes | 115058944486 |
| We submit written recommendations on a regular basis. | 癌症
> 癌症：血液 | 以實證為基礎的患者意見
> 將證據與洞見轉化為政策建議 | 10,000 | National | Regularly | 115056090120 |
| Attendance at relevant committee meetings and informal consultative sessions. | 先天性
> 先天性：心臟 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 10,000 | National | Rarely | 115003445044 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | 一般健康
> 醫療服務提供 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 100,000 | National | Regularly | 115009387424 |
| Activities include participation in forums and debates, submission of petitions to the 인권위 [국가인권위원회 – National Human Rights Commission]. | 患者倡議
> 病人權利 | 維護病人權益／提升生活質素
> 保護/改善患者體驗 | 5,000 | Regional | Regularly | 115033350867 |
互動
行動與倡議
7 提及
